This website uses cookies and other technologies to personalize content and ads on this and other websites and provide social media features. By clicking "I Agree" you consent to our use of tracking technologies and disclosure of tracking data to third party ad networks or social media companies for the purposes above. If you click "I Disagree" you can still use this website. For more information about Lilly’s privacy practice and to manage third-party preferences, click here.

HOME

Verzenio + fulvestrant

Explore the effectiveness, dosing, and common side effects of Verzenio + fulvestrant.

Female laying in the leaves with a dog

How effective is Verzenio + fulvestrant?

Verzenio was studied in a clinical trial of 669 women with hormone receptor‑positive (HR+), human epidermal growth factor receptor 2‑negative (HER2–) metastatic breast cancer (MBC), whose disease had progressed after hormone treatment: 446 patients were treated with Verzenio + fulvestrant, and 223 were treated with fulvestrant alone.

Verzenio is helping to raise the bar of what is possible in HR+, HER2− metastatic breast cancer treatment.

almost 4 years

Proven to help women live significantly longer

In a clinical study, women taking Verzenio + fulvestrant lived for a median of 46.7 months vs 37.3 months on fulvestrant alone, regardless of menopausal status

16.4 months

More time without disease progression

In the same study, Verzenio + fulvestrant delayed disease progression for a median of 16.4 months vs 9.3 months with fulvestrant alone

What is Overall Survival
  • Overall survival (OS) is how long someone lives with cancer, either after being diagnosed or starting treatment. When taking treatment, OS is the days, months, or years that treatment may add to life.

What is progression-free survival
  • Progression-free survival (PFS) is the amount of time during and after treatment that the cancer doesn’t get worse. In other words, PFS is how long cancer growth is delayed from the time a treatment is started.

  • Progression-free survival (PFS) is the amount of time during and after treatment that the cancer doesn’t get worse. Overall survival (OS) is how long someone lives with cancer after being diagnosed or starting treatment.

SELECT SAFETY INFORMATION

Verzenio may cause serious side effects, including:
Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea.

At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids.

tumor shrinkage

Twice as many women saw their tumors shrink

48.1% of patients on Verzenio + fulvestrant saw their tumors shrink vs 21.3% with fulvestrant alone

no detectable signs of cancer

Complete response: no detectable signs of cancer

In a clinical study, 3.5% of women on Verzenio + fulvestrant had a complete response, or no detectable sign of cancer, vs 0% with fulvestrant alone

tumor shrinkage of 30% or more

Partial response: tumor shrinkage of 30% or more

In a clinical study, 44.7% of women on Verzenio + fulvestrant had a partial response with tumor shrinkage of 30% or more vs 21.3% with fulvestrant alone

SELECT SAFETY INFORMATION

Verzenio may cause serious side effects, including:
Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. Tell your doctor right away if you have fever or chills.

Purpose and Safety Summary
Important Facts About Verzenio® (ver-ZEN-ee-oh). It is also known as abemaciclib.

Verzenio is a prescription medicine used to treat a type of breast cancer. It is a medicine you can take if:

  • You have a type of breast cancer called HR+/HER2– (hormone receptor positive/human epidermal growth factor receptor 2–negative) and the cancer has spread to other parts of the body (metastasized)
  • Verzenio is given along with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, along with fulvestrant in women whose disease has progressed after hormonal therapy, or by itself in adults whose disease has progressed after hormone therapy and prior chemotherapy

It is not known if Verzenio is safe and effective in children.

Warnings

Verzenio may cause serious side effects, including:

Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea.

At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids.

Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. Tell your doctor right away if you have fever or chills.

Verzenio may cause severe or life-threatening inflammation (swelling) of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:

  • trouble breathing or shortness of breath
  • cough with or without mucus
  • chest pain

Verzenio can cause liver problems. Tell your doctor right away if you have any of the following signs or symptoms of liver problems:

  • Feeling very tired
  • Loss of appetite
  • Pain on the upper right side of your stomach area (abdomen)
  • Bleeding or bruising more easily than normal

Verzenio may cause blood clots in your veins or lungs. These may be serious and have led to death. Tell your doctor if you have the following signs and symptoms of a blood clot:

  • Pain or swelling in your arms or legs
  • Fast breathing
  • Shortness of breath
  • Fast heart rate
  • Chest pain

Verzenio can harm your unborn baby. Use effective birth control during treatment and for at least 3 weeks after the last dose of Verzenio and do not breastfeed during treatment with Verzenio and for at least 3 weeks after your last dose. Verzenio may affect the ability of males to father a child.

Common side effects

The most common side effects of Verzenio include:

  • Nausea
  • Abdominal pain
  • Infections
  • Tiredness
  • Low red blood cell counts (anemia)
  • Low white blood cell counts (leukopenia)
  • Decreased appetite
  • Vomiting
  • Headache
  • Low platelet counts (thrombocytopenia)
  • Hair thinning or hair loss (alopecia)

These are not all the possible side effects of Verzenio.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before you use Verzenio, tell your doctor:

  • If you have fever, chills, or other signs of infection
  • Have liver or kidney problems
  • About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take a medicine that contains ketoconazole. Avoid grapefruit products while taking Verzenio. Grapefruit may increase the amount of Verzenio in your blood
How to take
  • Use Verzenio exactly as your doctor tells you
  • Take your doses of Verzenio at about the same time every day
  • If you vomit or miss a dose take your next dose at your regular time. Do not take 2 doses of Verzenio at the same time to make up for the missed dose
  • If you take too much Verzenio, call your doctor or go to the nearest hospital emergency room right away
Learn more

For more information, call 1-800-545-5979.

This summary provides basic information about Verzenio but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Verzenio and how to take it. Your doctor is the best person to help you decide if Verzenio is right for you.

Verzenio® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

AL CON BS 20SEP2019

Are you a US healthcare provider?

The information contained in this section of verzenio.com is intended for US healthcare providers.

Are you a US healthcare provider?

The information contained in this section of verzenio.com is intended for US healthcare providers.

You are now leaving verzenio.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party website you visit. We encourage you to read the privacy policy of every website you visit.

Click “Return” to go back to verzenio.com or “Continue” to proceed.